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Summary Monoclonal and polyclonal antibodies against placental alkaline phosphatase (PLAP) were
evaluated for tumour immunolocalization of human PLAP-producing Hep 2 tumours in nude mice. The
antibodies were labelled with 125I and injected i.p. in mice with developing Hep 2 tumours. The distribution
of 125I-anti PLAP in various tissues showed that the labelled antibody was enriched in the tumour, the mean
concentration ratio being 7.1 and 6.8 for polyclonal and monoclonal antibodies, respectively. A PLAP
negative tumour (RD) showed a mean ratio of 1.2. There was a positive correlation between PLAP content
and uptake of labelled antibody in the tumours. Hep 2 tumour cells in tissue culture showed 100% positivity
for PLAP, while imprints of the tumour after passage in nude mice showed 40-50% positivity. PLAP offers
potential as a useful marker for localizing tumours in humans.
Human placental alkaline phosphatase (PLAP; EC
3.1.3.1) is normally synthesized by trophoblasts
from the 12th week of pregnancy. Recent studies
have indicated that very small amounts of
placental-like ALP forms also occur in endocervix
(Goldstein et al., 1980) and testis (Chang et al.,
1980). Placental-like ALP is also ectopically
synthesized by some tumours (Fishman et al.,
1968). Elevated levels of PLAP are observed in the
sera of about 12% of patients with any type of
cancer and frequently in patients with ovarian
tumours (Fishman et al., 1979). In seminoma of the
testis very high tissue levels were found (Wahren et
al., 1979). Assays of PLAP in serum of seminoma
patients appear to be of clinical value (Lange et al.,
1982; Jeppsson et al., 1983; Javadpour, 1983). In
50-75% of patients with seminomas elevated levels
were seen, depending on the stage of tumour
disease (Jeppsson et al., 1983). PLAP is normally
bound to the outer surface of the cytoplasmic
membrane and so theoretically appears to be a
suitable target for radioimmuno-detection.
This paper describes immunolocalization of a
PLAP-producing human tumour in nude mice as
well as a study of single cells from this tumour
using both polyclonal and monoclonal antibodies
against PLAP.
Material and methods
Polyclonal antibodies
New Zealand rabbits were immunized with 50jg of
purified PLAP of the 2-1 phenotype, bled and
boosted monthly during 2 years. The serum IgG
fraction was isolated on a protein A-Sepharose
column according to manufacturers instruction
(Pharmacia, Uppsala, Sweden). Rabbit anti-CEA
antibodies were prepared and purified in a similar
way.
Monoclonal antibodies
The monoclonal antibody (F11, IgGl, K) against
PLAP type 1 was produced as described (Millan et
al., 1982). The antibody was affinity purified on a
PLAP-Sepharose column. The determinant detected
by the F,, antibody, was greatly altered by
reduction and carboxymethylation indicating that
the antibody probably reacts with a protein
determinant. Monoclonal antidistemper virus
antibody (mouse IgGl, K) was a gift from Dr. Claes
Orvell, National Bacteriological Laboratory,
Stockholm, and used for control purposes.
Tumour cells
The following human tumour cell lines passaged at
the National Bacteriological Laboratory were used:
HeLa, strain Hep 2 which produces PLAP; colon
adenocarcinoma LS 174T, which produces CEA but
no PLAP; Detroit 562 cells, which produce CEA;
and rhabdomyosarcoma RD, which produces
neither CEA nor PLAP (Hedin et al., 1982).
LS 174T cells were grown in tissue culture with
RPMI 1640 media supplemented with 10% foetal
bovine serum, the other cells with modified Eagle's
medium supplemented with 8% foetal bovine
serum.
Animal model
Nude mice (BALB/c nu/nu, Bomholtgaard, Ry,
Denmark) were inoculated s.c. behind the front leg
with trypsinized cells from tissue culture. Tumour
formation by LS 174T was achieved by injecting
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2 x106 cells while 1-5 x I07 cells were needed to
produce Hep 2 and RD tumours. Tumours were
observed macroscopically 6-10 days after
inoculation.
Localization experiments
The IgG preparations (50jg) were labelled with
1 mCi 1251 using the chloramine T method to a
specific activity of 10uCi g- . Free iodine was
removed on a Sephadex G50 column. When the
radiolabelled Fl was passed through a PLAP-
Sepharose column, 80% of the labelled antibody
bound. In radioimmunoassay with a solid phase of
the respective antigen, 25% labelled rabbit anti-
PLAP bound to PLAP and 20% of radiolabelled
polyclonal anti-CEA bound to CEA.
The radioactive antibodies (1-2 ug) diluted in
300,l physiological saline containing 1 mgml -1
bovine serum albumin (BSA) as carrier protein,
were injected i.p. when the tumours had been
growing for 10 days. Mice were sacrificed at
different times after administration of labelled
antibody and the organs were removed, perfused
with saline, weighed and radioactivity determined in
a gamma counter. Lysates were made for
radioimmunoassays by mixing 4 volumes of
distilled water with tumour tissue, followed by
ultrasonication.
The distribution of radiolabelled antibody in
nude mice was expressed as concentration ratios
(Hedin et al., 1982) calculated as follows:
Concentration ratio
(radioactivity in specified tissue)
x (wt. of whole mouse)
(wt. of specified tissue)
x (radioactivity of whole mouse)
Immunofluorescence (IF)
Indirect IF was performed on tissue cultured cells
and on imprints of tumours grown in nude mice.
The cells were air-dried or fixed for 3min with
methanol at room temperature. Air-dried
preparations resulted in higher IF intensity and
were therefore used for fluorometry despite the fact
that the morphology was better preserved with
methanol-fixed cells. The preparations were
incubated in a moist chamber for 30min with
antibody, rinsed with phosphate buffered saline
(PBS) and incubated for 30min with fluorescein-
isothiocyanate (FITC) conjugated sheep anti-rabbit
or anti-mouse IgG (National Bacteriological
Laboratory, Stockholm, Sweden). Blocking
experiments were performed by sequentially
incubating with mouse-anti PLAP followed by
rinsing, rabbit anti-PLAP and FITC anti-rabbit; or
with rabbit anti-PLAP, rinsing mouse anti-PLAP
and FITC anti-mouse antibodies. The fluorescence
intensity of single cells was measured with a Zeiss
Standard Universal microscope combined with a
Zeiss microscope photometer MPM, at 530nm. For
measurements, the cells were excited individually in
measuring diaphragms. The smears were scanned
and 40-60 single tumour cells measured for each
preparation. The intensity of the emitted light was
expressed as relative units, F, after correction for
background values without cells in the same
preparation. A visual estimation of the per cent
stained cells was also made.
Radioimmunoassays (RIA)
The concentration of PLAP in dissected organs,
tumours and in vitro grown tumour cells was
determined by a specific double antibody solid
phase radioimmunoassay (Holmgren et al., 1978)
with intra- and interassay variations of < 15%. The
sensitivity of the assay was 12ngml-1. CEA was
determined by a specific RIA as described
(Zimmerman, 1979) with a sensitivity of 1 ngmli.
Statistical method
The Wilcoxon-Mann-Whitney non-parametric test
was used to estimate differences between groups.
Results
The distribution of radiolabelled polyclonal anti-
PLAP antibodies in different tissues as a function
of time after injection of labelled antibody was
determined. The concentrations of antibody in the
tumour and organs were related to the
concentration in the whole mouse, forming a
concentration ratio. These ratios remained rather
constant for the different tissues at Day 2, 4 and 6,
while tumour concentration ratio was maximal at
Day 4 (Table I). The ratio for blood decreased with
time. Day 4 was used for subsequent experiments.
The localization of 1251 polyclonal and monoclonal
anti-PLAP and anti-CEA to Hep 2 grown as solid
tumours in nude mice is summarized in Figure 1.
Both polyclonal and monoclonal anti-PLAP
localize to the Hep 2 tumour tissue. The con-
centration ratios in blood of the summarized results
at Day 4 were similar to that of tumours.
The distribution of polyclonal anti-CEA in the
mice is also shown in Figure 1. With anti-CEA
injected to Hep 2 carrying animals, there were no
significant differences between the tumour and the
other organs. The concentration ratio in blood was
higher than in any organ or the tumours.TUMOUR LOCALIZATION WITH ANTI-PLAP ANTIBODIES 125
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Figure 1 Mean concentration ratio+sd after 4 days for Hep 2 tumours and other nude mouse tissues when
using polyclonal anti-PLAP (1, 11 mice), monoclonal anti-PLAP (U, 12 mice) and polyclonal anti-CEA (iii,
5 mice) antibodies.
Table I Mean concentration ratios of 125I-labelled rabbit
anti-PLAP in various organs of nude mice bearing Hep 2.
Two mice were sacrificed at each time point
Concentration ratio
Day 2 Day 4 Day 6
Tumour 7.0 8.5 7.0
Heart 1.2 1.2 1.2
Skin 2.2 2.4 2.0
Liver 1.5 1.4 1.0
Kidney 2.5 2.7 2.6
Lung 2.0 2.0 2.0
Intestine 1.0 0.9 0.7
Thyroid 2.2 2.0 1.5
Spleen 2.8 1.5 1.4
Muscle 0.9 0.9 0.8
Blood 7.1 4.8 4.8
Mean total
radioactivity, 19 7 3
% of injected
Table II summarizes the specific tumour
concentration ratios obtained by injecting 1251I
labelled anti-PLAP antibodies to Hep 2, LS 174T
and RD tumour bearing mice as well as control
monoclonal antibody administered to mice with
Hep 2 tumour.
Table II Mean concentration ratio in the tumour for
different cell lines and antibodies
Tumour
cells in Concentration
nude mice Antibody n ratio+sd
Hep 2 Polyclonal 11 7.1 + 1.2
anti-PLAP
Hep 2 Monoclonal 12 6.8+3.4
Fil anti-
PLAP
Hep 2 Polyclonal 5 3.6+1.5
anti-CEA
Hep 2 Monoclonal 3 2.9+0.1
anti-
distemper
LS 174T Polyclonal 2 4.6; 0.6
anti-PLAP
RD Polyclonal 2 1.4; 1.0
anti-PLAP
There was a significant difference in the
concentration ratio of polyclonal anti-PLAP in
Hep 2 compared to the other tumours LS 174T and
RD (P<O.O1). The difference was also significant
comparing localization of F,1 monoclonal anti-
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PLAP in Hep 2 with localization in the other
tumours (P<0.01) and comparing the anti-PLAP
F1l antibody in Hep 2 with localization of
antibodies to CEA and distemper in Hep 2
(P<0.01). No significant difference was seen
between the concentration ratios of polyclonal anti-
PLAP and monoclonal F1l in Hep 2.
Measurements of PLAP by RIA indicated high
concentrations of the antigen in Hep 2 tumour
lysates but low in liver tissue and blood of the same
animals (Table III). There was no detectable CEA
in Hep 2 cells.
Table III PLAP and CEA contents measured by RIA of
tumours and tissues
Tissues of
Tissues nude mice PLAP+sd CEA+sd
Hep2a tumour ngg'- 3558+2689 < 100
liver ngg 1 <20 <20
blood ngml-' <20 <20
LS 174T tumourngg-1 <100 51278+
31820
blood ngml-P' <20 51+42
RD tumour ngg-1 < 100 < 100
blood ngml-1 <20 <20
Hep 2 TCb
nglO cells 2800c <20
LS 174T TC
ng 10- 7 cells not done 5854
aAfter transplantation in nude mice.
bTissue cultured cells.
cSince the weight of 107 Hep 2 cells is - 0.05g, the
PLAP content of Hep 2 in TC, wet weight, is - 56,ugg-1.
Hep 2 tumours taken from sacrificed animals
contained PLAP (mean 3110ngg-1), but only
background levels of CEA. There was a positive
correlation between PLAP concentration in the
tumours and amount of labelled antibody localized
to the tumour (r=0.66, Table IV), but between
tumour weight and concentration ratio the relation
was inverse (r= -0.50). The results of immuno-
fluorescence studies are shown in Table V. All
Hep 2 cells in culture showed positive staining for
PLAP. After they have been growing in nude
mice and imprints were made, 40-50% of the cells
were stained with polyclonal or monoclonal anti-
PLAP. The mean intensity of stained cells was
higher with polyclonal anti-PLAP antibodies than
with the F1l monoclonal antibody. This, however,
is most likely a question of concentration of the
active IgG in the antiserum, since rabbit anti-PLAP
when further diluted showed the membrane staining
pattern characteristic for F1l (Figure 2).
Monoclonal anti-PLAP blocked 50% of the
polyclonal anti-PLAP fluorescence intensity/cell.
Polyclonal anti-PLAP inhibited the staining with
monoclonal anti-PLAP to <5%. Anti-CEA or
anti-distemper did not inhibit anti-PLAP staining of
Hep 2.
Monoclonal anti-distemper virus or normal
mouse Ig did not stain in vitro grown Hep 2, Hep 2
imprints or RD. Anti-CEA stained tissue-cultured
LS 174T and Detroit cells, but not Hep 2 or RD
(Table V).
Discussion
The present study was designed to explore the
potential use of placental alkaline phosphatase as a
target for immunodetection. This may be beneficial
in diagnosis and monitoring of treatment in
patients with seminoma (Wahren et al., 1979;
Lange et al., 1982; Jeppsson et al., 1983). Our
results show that both polyclonal and monoclonal
antibodies against PLAP localize to PLAP-
producing tumours but not to tumours in which
PLAP was not detectable. Evidence for the specific
localization was the in vitro immunofluorescence of
membrane and cytoplasm of the same type of
tumour cells as those used in vivo. The in vitro
localization could be blocked by polyclonal anti-
PLAP and, as expected, partially blocked by
monoclonal anti-PLAP, but was not blocked by
control sera. The same type of blocking was not
Table IV Relation between tumour weight, concentration ratio and PLAP concentration in Hep 2 and LS 174T
tumours
Concentration ratio
Thmour weight of125I anti-PLAP, PLAP concentration CEA concentration
in g, range mean (range) ngg-1, mean (range) ngg 1, mean (range)
Hep 2 0.142-0.455 6.2 (2.6-10.5) 3110 (500-9800) 66 (39-98)
LS 174T 0.100 0.6 <70 31836TUMOUR LOCALIZATION WITH ANTI-PLAP ANTIBODIES 127
Table V Mean fluorescence values and percent tumour cells stained with anti-PLAP and anti-CEA
antibody
F values with immunofluorescence+sd
(% stained cells)
Rabbit Rabbit
anti-PLAPa F1l anti-CEA
Hep 2 imprint 46±7 (40%) 15+5 (50%) <5 (0%,)
Hep 2 TCb 115+29 (100%) 20+3 (100%) 7+2 (9%)
LS 174T TC <5 (0%) <5 (0%) nmc (50%)
Detroit 562 TC <5 (0%) <5 (0%) 77+22 (25%)
RD TC <5 (0%) <5 (0%) <5 (0%)
'All antibody preparations were diluted 1:5 for staining, all preparations were air-dried.
"Tissue cultured cells.
Cnm =not measured due to overlapping cell growth.
Figure 2 Immunofluorescence photograph of Hep 2 cells grown in culture and stained with rabbit anti-
PLAP (a, intracytoplasmic and cell membrane staining) and monoclonal anti-PLAP (b, cell membrane
staining). x 576.
attempted in vivo, but it is unlikely that complete
blocking should occur in the comparatively large
tumours carried by the nude mice.
The amounts of labelled antibody bound to the
tumour showed a positive although not very high
correlation with the PLAP concentration. Smaller
tumours had somewhat higher mean concentration
ratios than larger tumours. This would be an
advantage if the method was to be used for
diagnostic purposes. The control anti-CEA
antibodies gave variable binding ratios to Hep 2.
The reasons are not clear, since the immuno-
fluorescence studies and RIA determinations
show very low CEA content in Hep 2 cells.
Both the rabbit polyclonal antibodies and the F1l
monoclonal antibody against PLAP were successful
in localizing the tumour as compared to other
tissues. The concentration ratios of blood however,
were as high as for the tumour. This was previously
seen also with anti-CEA injected to mice with
CEA-containing tumours (Mach et al., 1974; Hedin
et. al., 1982). The blood concentration ratio
thereafter declined, giving better tumour
localization. The high initial concentration ratio in
blood could represent circulating radiolabelled anti-
PLAP, partially broken-down labelled antibody and
perhaps free iodine from the broken-down injected
material. There is probably not much binding of
antibody to circulating antigen, since the PLAP
concentration in blood of the nude mice was non-
measurable. In future it would probably be an
advantage to use fragments of antibodies for128 A. JEPPSSON et al.
immunolocalization, since these are excreted
quicker than whole IgG.
While 100% Hep 2 cells grown in vitro stained
with high intensity for PLAP antibodies, the
percentage and intensity decreased in the solid
tumours after in vivo growth. Other authors have
recently demonstrated that different subclones of
HeLa cells expressing PLAP in vitro, when grown
in vivo undergo modulation of their alkaline
phosphatase pattern, by expressing intestinal type
or tissue-unspecific type alkaline phosphatase at the
expense of PLAP expression (Singer et al., 1980). It
is conceivable that the percentage of cells that still
express PLAP are also undergoing modulation and
thus contain a lower total amount. In tissue-
cultured Hep 2 cells, the mean amount of PLAP
appeared to be higher than in cells passed in the
nude mice.
PLAP is produced by a highly polymorphic gene
locus that includes more than 18 allelic forms as
described by electrophoresis. Normally PLAP is
expressed in second and third trimester placentae,
but also by normal endocervix. The Hep 2 cells
that were used for our experiments are subcloned
from HeLa cells derived from a cervix carcinoma.
HeLa cells have been shown to express the
homozygote type 1 (old nomenclature type S) allelic
forms of PLAP (Beckman et al., 1970). The Fl1
monoclonal antibody used in the present study
reacts with the type 1 form of PLAP but shows
restricted specificity since it does not react with the
type 2 allelic form of PLAP (Millan et al., 1982). In
contrast, tumours like seminoma and different
ovarian carcinomas express a PLAP-like enzyme
(Wahren et al., 1979; Benham et al., 1981) that
although cross-reactive with polyclonal antibodies
to PLAP, can be distinguished from the normal
placental phenotypes by use of different
monoclonal antibodies (Millan et al., unpublished
results). A high percentage of these tumour
enzymes is indeed non-reactive with the F,j
monoclonal antibody (Millan et al., 1982). Thus
polyclonal antibodies or monoclonal antibodies
with specificities to common determinants should
be used to allow radioimmunodetection of
seminomas.
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